Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from NurExone Biologic ( (TSE:NRX) ).
NurExone Biologic reported new laboratory data showing that its proprietary exosomes significantly suppress inflammatory activity in immune cells, markedly outperforming a commercially available exosome product. The company’s exosomes reduced key inflammatory cytokines IL-6 by more than 86% at all tested concentrations and TNF-alpha by over 60% at the highest concentration, with a clear dose-dependent effect, which supports its ExoPTEN regenerative approach and reinforces the analytical and quality framework underlying its exosome-based drug delivery platform.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB and Frankfurt markets, focused on developing regenerative exosome-based therapeutics, particularly for central nervous system indications using exosomes derived from human bone marrow–derived mesenchymal stem cells.
Average Trading Volume: 47,811
Technical Sentiment Signal: Buy
Current Market Cap: C$49.7M
Learn more about NRX stock on TipRanks’ Stock Analysis page.